# PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

> **NCT00766324** · PHASE2 · COMPLETED · sponsor: **Nerviano Medical Sciences** · enrollment: 118 (actual)

## Conditions studied

- Metastatic Hormone Refractory Prostate Cancer

## Interventions

- **DRUG:** PHA-739358
- **DRUG:** PHA-739358

## Key facts

- **NCT ID:** NCT00766324
- **Lead sponsor:** Nerviano Medical Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2011-03
- **Final completion:** 2011-04
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2014-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00766324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00766324, "PHA-739358 for Treatment of Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00766324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*